Currently, SOTIO is conducting three clinical studies of its investigational cancer therapies: a Phase 1/2 clinical trial evaluating the safety and preliminary efficacy of SOT102 in monotherapy and in combination with established standard of care therapies; a Phase 1/2 clinical trial for its CAR T cell therapy candidate, BOXR1030; and a Phase 1 clinical trial of SOT201, a next-generation PD-1-targeting immunocytokine.